Voyager Therapeutics Q4 net loss narrows

Voyager Therapeutics

09/03/2026 20:10

Overview

Biotechnology firm's Q4 collaboration revenue rose yr/yr

Company ended 2025 with $202 mln cash, runway expected into 2028

Net loss for Q4 decreased compared to last year

Outlook

Voyager expects first-in-human dosing for VY1706 in Alzheimer's disease in H2 2026

Voyager plans to maintain cash runway into 2028

PIPELINE ADVANCEMENT - Significant developments expected in 2026, including clinical entry of neuro gene therapies and tau-targeting data

Result Drivers

COLLABORATION REVENUE - Q4 revenue increased due to higher recognition under the Neurocrine agreement

CASH POSITION -Ended 2025 with cash position of $202 million

Research and development expenses were $36.0 million for the three months ended December 31, 2025, compared to $35.6 million for the same period in 2024,

Company press release: ID:nGNX12N6Wq

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Collaboration Revenue
$15.34 mln
Q4 EPS
-$0.46
Q4 Net Income
-$27.43 mln
Q4 Basic EPS
-$0.47
Q4 Operating Income
-$29.93 mln
Q4 Pretax Profit
-$27.42 mln


Analyst Coverage

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 12 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy."

Wall Street's median 12-month price target for Voyager Therapeutics Inc is $12.00, about 207.7% above its March 6 closing price of $3.90

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)